Journal of the Chinese Medical Association
Volume 69, Issue 9 , Pages 436-438, September 2006

Coronary Revascularization in a Patient with Immune Thrombocytopenic Purpura

  • Man-Cai Fong

      Affiliations

    • Division of Cardiology, Intensive Care Unit, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
  • ,
  • Kuan-Chun Chen

      Affiliations

    • Division of Cardiology, Intensive Care Unit, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
  • ,
  • Hsin-Bang Leu

      Affiliations

    • Division of Cardiology, Intensive Care Unit, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
  • ,
  • Lung-Ching Chen

      Affiliations

    • Intensive Care Unit, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
    • Corresponding Author InformationCorrespondence to: Dr Lung-Ching Chen, Intensive Care Unit, Department of Medicine, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan, R.O.C.

Received 12 October 2005; accepted 24 May 2006.

Immune thrombocytopenic purpura (ITP) is a bleeding disorder characterized by premature platelet destruction mediated by autoantibodies. We report a 71-year-old ITP patient with concomitant acute coronary syndrome. Cardiac catheterization was performed through the right radial artery and premedicated with immunoglobulin. Left anterior descending artery was stented, followed by clopidogrel treatment for 7 weeks without major bleeding complication. The patient has been observed for 2 years without clinical restenosis. We suggest that stent implantation is a safe treatment in this special condition. Treatment should be individualized, but it is still a challenge to balance bleeding and thrombosis complication.

Key Words:  angioplasty , antibodies , immune system , platelet aggregation inhibitors

No full text is available. To read the body of this article, please view the PDF online.

 

PII: S1726-4901(09)70287-4

doi:10.1016/S1726-4901(09)70287-4

Journal of the Chinese Medical Association
Volume 69, Issue 9 , Pages 436-438, September 2006